Evaluation of Post-Implantation Local Effects According to ISO 10993-6:2016: A Critical Step in the Biocompatibility of Medical Devices
To ensure that medical devices can be used safely in the human body, it is essential not only to evaluate systemic toxicity profiles, but also the local tissue reactions they may cause at the implantation site must be comprehensively evaluated. An implant placed in the body is in constant interaction with the surrounding tissues, and this interaction can lead to various local responses such as inflammation, fibrosis, tissue necrosis, granuloma formation, or a foreign body reaction. This is precisely where the ISO 10993-6:2016 standard comes into play. This international standard defines the necessary test methods, tissue selection criteria, and histopathological evaluation parameters for assessing the local effects of medical devices and biomaterials following implantation. Our laboratory conducts implantation tests under the scope of ISO 10993-6:2016 in compliance with GLP and using the most up-to-date scientific approaches.
Scope and Importance of the ISO 10993-6:2016 Standard
ISO 10993-6, as part of the series on the biological evaluation of medical devices, focuses on the evaluation of local effects following implantation. The 2016 revision of the standard includes significant updates compared to previous versions. The most notable feature of this revision is the adoption of a risk-based approach in test design and the systematization of histopathological evaluation criteria. The standard requires that the implant be placed in an appropriate anatomical region using a suitable animal model, consistent with the implant’s intended clinical use, and that the reactions in the surrounding tissue be evaluated macroscopically and microscopically at specific time points.
The primary objectives of ISO 10993-6:2016 are as follows:
- To determine the type, severity, and temporal course of local tissue reactions forming around the implant.
- To establish the biological acceptability (biocompatibility) of the implant material.
- To evaluate the transition of the inflammatory response from the acute to the chronic phase and the tissue healing process.
- To investigate the effects of the implant’s degradation products on local tissue.
- To create a biocompatibility dossier supporting the device’s clinical safety based on the data obtained.
Critical Parameters in Test Design
The scientific validity of an implantation study under ISO 10993-6:2016 depends on the test design being structured with the correct parameters. The table below summarizes the critical design parameters that must be considered in implantation tests and their implementation in our laboratory:
| Parameter | Standard Requirements | Our Laboratory’s Practice |
|---|---|---|
| Animal Model Selection | A species appropriate for the device’s intended clinical use; rodents (rats, mice), rabbits, dogs, sheep, pigs, or primates | Before each study, the most appropriate species is selected based on the device’s size, implantation site, and clinical scenario; rats and rabbits are the most commonly used models. |
| Implantation Site | Anatomical regions reflecting clinical use, such as subcutaneous, intramuscular, intraperitoneal, intraosseous, or brain tissue | The device’s target tissue is determined; for example, bone is selected for orthopedic implants, while the subcutaneous or intramuscular region is chosen for soft tissue implants. |
| Control Material | Use of a negative control (e.g., high-density polyethylene—HDPE) and, when necessary, a positive control | A validated negative control material is used in every study; the control tissue response is used as a reference for the validity of the results. |
| Number and Size of Implants | Test and control implants in each animal; implant size must be appropriate for the species and region | The number of animals is optimized by placing more than one implant per animal; implant sizes are prepared in accordance with the standard. |
| Observation Periods | Short-term (1–4 weeks) and long-term (12–26 weeks or longer) evaluation time points | Evaluation points at 1, 4, 12, and 26 weeks are planned based on the device’s contact duration; for permanent implants, periods of 26 weeks or longer are applied. |
| Histopathology | Complete histopathological examination of the tissue surrounding the implant; scoring of parameters such as inflammation, fibrosis, necrosis, vascularization, and foreign body reaction | Our experienced veterinary pathologists evaluate all parameters using a semi-quantitative scoring system in accordance with INHAND terminology. |
Histopathological Evaluation Parameters and Scoring System
ISO 10993-6:2016 recommends the use of a semi-quantitative scoring system for the evaluation of local tissue reactions following implantation. This system involves scoring observed histopathological findings on a scale from 0 (absent) to 4 (severe) based on their severity and statistically comparing the difference between the test material and the control material. The table below details the key histopathological parameters evaluated and the scoring criteria:
| Parameter | Score 0 | Score 1 (Mild) | Score 2 (Moderate) | Score 3 (Marked) | Score 4 (Severe) |
|---|---|---|---|---|---|
| Polymorphonuclear Leukocyte (PMN) Infiltration | Absent | Rare scattered cells | Focal clusters | Widespread infiltration | Dense, widespread infiltration and abscess formation |
| Lymphocyte/Plasma Cell Infiltration | Absent | Rare scattered cells | Focal clusters | Widespread infiltration | Intense, widespread infiltration with follicle formation |
| Macrophage Infiltration | Absent | Rare scattered cells | Focal clusters | Widespread infiltration, early granuloma formation | Prominent granuloma formation, multinucleated giant cells |
| Necrosis | Absent | Minimal, focal cell death | Focal tissue necrosis | Diffuse tissue necrosis | Massive necrosis involving extensive areas |
| Fibrosis / Fibrotic Capsule Formation | None | Thin fibrotic band (a few cell layers) | Medium-thickness fibrotic capsule | Thick fibrotic capsule extending into surrounding tissue | Very thick, extensive fibrotic tissue with contracture formation |
| Neovascularization | Normal tissue vascularity | Slightly increased capillary density | Marked capillary proliferation | Widespread neovascularization | Dense, irregular vascular network |
| Foreign-body giant cells | Absent | Rare, isolated giant cells | Focal clusters of giant cells | Widespread presence of giant cells within a granulomatous structure | Marked granulomatous reaction with numerous giant cells |
| Fat Infiltration / Steatosis | Absent | Minimal fat accumulation | Focal fat infiltration | Widespread fat infiltration | Intense fat accumulation disrupting tissue structure |
Implantation Site Selection Guide
ISO 10993-6:2016 requires that the implantation site be selected in accordance with the device’s intended clinical use. The table below summarizes the recommended implantation sites and animal models for different medical device categories:
| Device Category | Example Devices | Recommended Implantation Site | Recommended Animal Model | Recommended Observation Periods |
|---|---|---|---|---|
| Soft tissue implants | Wound dressings, hemostatic agents, tissue adhesives, aesthetic fillers | Subcutaneous, intramuscular | Rat, rabbit | 1, 4, 12 weeks |
| Orthopedic implants | Bone screws, plates, prostheses, bone grafts, joint replacements | Intraosseous – femur, tibia, skull | Rabbit, dog, sheep | 4, 12, 26 weeks or longer |
| Cardiovascular devices | Stents, vascular grafts, heart valves, catheters | Intravascular, intramuscular | Dog, pig, sheep | 4, 12, 26 weeks |
| Neurological devices | Deep brain stimulators, neural electrodes, shunts | Brain tissue, spinal canal | Rat, rabbit, dog | 4, 12, 26 weeks |
| Dental implants | Dental implants, bone augmentation materials, membranes | Jawbone (mandible, maxilla), subcutaneous | Rabbit, dog, pig | 4, 12, 26 weeks |
| Ophthalmic implants | Intraocular lenses, glaucoma drainage devices | Intraocular, subconjunctival | Rabbit | 1, 4, 12 weeks |
| Absorbable materials | Biodegradable sutures, temporary scaffolds, drug delivery systems | Subcutaneous, intramuscular, intraosseous | Rat, rabbit | Multiple time points based on the material’s degradation profile (1, 4, 12, 26, 52 weeks) |
Differences Between ISO 10993-6:2016 and the 2009 Version
The ISO 10993-6:2016 revision contains significant differences from the previous version (ISO 10993-6:2009). Understanding these differences is critical for updating existing biocompatibility dossiers and planning new studies:
| Feature | ISO 10993-6:2009 | ISO 10993-6:2016 | Impact |
|---|---|---|---|
| Approach | General test requirements, prescriptive approach | Risk-based, design tailored to the device’s clinical use | Test planning is now based on the device’s specific risk profile; unnecessary tests are reduced. |
| Evaluation Criteria | Limited list of parameters, basic inflammation assessment | Expanded and detailed parameters; reference to INHAND terminology | Histopathological evaluation is more comprehensive and standardized. |
| Evaluation of Degradation Products | Unclear, limited guidance | A detailed evaluation of the local effects of degradation products for absorbable materials is now required | The test strategy for biodegradable devices has been clarified. |
| Statistical Analysis | Limited guidance | More detailed guidance for the statistical comparison of differences between test and control materials | The scientific validity and defensibility of the results have increased. |
| Imaging Methods | Macroscopic and microscopic examination | References to radiography, microtomography (micro-CT), and other imaging methods have been added where necessary | Advanced imaging options have been provided, particularly for the evaluation of osseointegration in bone implants. |
Conducting ISO 10993-6:2016 Studies in Our Laboratory
In our GLP-certified laboratory, we conduct implantation tests under ISO 10993-6:2016 in full compliance with international standards.
Our experienced surgical team ensures that implants are placed under sterile conditions and in accordance with standard surgical procedures. During the postoperative period, the animals’ health status is monitored daily; pain management and infection prophylaxis are meticulously administered by our veterinarians. At the conclusion of the study, the tissues surrounding the implant are excised, histological sections are prepared, and evaluated by our experienced veterinary pathologists using a semi-quantitative scoring system. The data obtained are presented in a comprehensive biocompatibility report, which includes a statistical analysis of the differences between the test material and the negative control.
Frequently Asked Questions
| Question | Answer |
|---|---|
| For which medical devices is the ISO 10993-6 implantation test mandatory? | It is required for all devices that are implanted into the body or come into prolonged contact with tissue. In particular, implantation evaluation in accordance with ISO 10993-1 is mandatory for orthopedic implants, cardiovascular devices, dental implants, tissue fillers, surgical sutures, and neurological devices. |
| Which animal species should be selected for implantation testing? | The choice of species depends on the device’s size, the implantation site, and its intended clinical use. Rats and rabbits are recommended for small soft-tissue implants; dogs, sheep, or pigs for orthopedic and cardiovascular devices; and rats, rabbits, or dogs for neurological devices. |
| How long is the test duration? | Observation periods depend on the device’s contact time. For short-term contact devices, 1–4 weeks; for permanent implants, 12–26 weeks; for absorbable materials, up to 52 weeks depending on the degradation profile. Including reporting and quality assurance reviews, the total duration ranges from 3 to 8 months. |
| What should be used as the negative control material? | ISO 10993-6:2016 recommends low-density polyethylene (HDPE) or a similar material with proven biocompatibility as a negative control. The control material must be prepared in the same size and shape as the test implant and placed in the same anatomical region. |
| How does the test design differ for absorbable materials? | For biodegradable materials, multiple time points are planned to capture the different stages of the degradation process. Additionally, the effects of degradation products on local tissue are evaluated histopathologically. ISO 10993-6:2016 defines specific evaluation requirements for such materials. |
| In which regulatory submissions are ISO 10993-6 results used? | They are used in the EU Medical Device Regulation (MDR 2017/745), U.S. FDA 510(k) and PMA submissions, Turkish TİTCK approval processes, and biocompatibility assessments by other international regulatory authorities. They are also a mandatory part of the technical dossier required for obtaining the CE mark. |
Implantation is the process in which medical devices interact most deeply with the body, and scientifically proving the safety of this interaction is a top priority for every responsible manufacturer. With our implantation tests conducted in accordance with ISO 10993-6: 2016, we evaluate the local tissue compatibility of your device according to the highest scientific standards and provide reliable and defensible data for your regulatory submissions. To plan an implantation study for your medical device, contact us at our GLP-certified laboratory.
